We were recently awarded a National Science Foundation (NSF) Phase I Small Business Innovation Research (SBIR) grant for $225,000 to develop AlphaSeq: a cell-based platform that will accelerate cancer drug development by enabling high-throughput and quantitative characterization of protein-protein interactions. This SBIR grant is aimed at expanding the capabilities of AlphaSeq for screening interactions with challenging proteins and insoluble small molecule drugs. For more information check out our press release and an article written about the award in GeekWire.
A-Alpha Bio Awarded NSF Phase I SBIR Grant
Updated: Mar 23, 2020